Login to Your Account

Dendreon's Trp-p8 Gene Platform Garners $110M Genentech Deal

By Kim Coghill

Wednesday, August 14, 2002
Dendreon Corp. could gain more than $110 million in a deal with Genentech Inc. to develop monoclonal antibodies, small molecules and other products from Dendreon's preclinical Trp-p8 gene platform. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription